| Primary |
| Product Used For Unknown Indication |
54.3% |
| Prophylaxis |
5.4% |
| Helicobacter Infection |
4.7% |
| Prophylaxis Against Gastrointestinal Ulcer |
4.7% |
| Gastrooesophageal Reflux Disease |
3.1% |
| Herpes Virus Infection |
3.1% |
| Infection |
3.1% |
| Fungal Infection |
2.3% |
| Gastric Ulcer |
2.3% |
| Hypertension |
2.3% |
| Small Intestine Transplant |
2.3% |
| Constipation |
1.6% |
| Infection Prophylaxis |
1.6% |
| Nausea |
1.6% |
| Pneumonia |
1.6% |
| Premedication |
1.6% |
| Prophylaxis Against Graft Versus Host Disease |
1.6% |
| Pyrexia |
1.6% |
| Diuresis |
0.8% |
| Diuretic Therapy |
0.8% |
|
| Toxic Epidermal Necrolysis |
13.8% |
| Drug-induced Liver Injury |
10.3% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
6.9% |
| Gastrointestinal Perforation |
6.9% |
| Rash |
6.9% |
| Vision Blurred |
6.9% |
| Dyspnoea |
3.4% |
| Ectopic Pregnancy |
3.4% |
| Enterocolitis Haemorrhagic |
3.4% |
| Erythema Multiforme |
3.4% |
| Eye Pain |
3.4% |
| Gait Disturbance |
3.4% |
| Hydrocephalus |
3.4% |
| Ileus Paralytic |
3.4% |
| Osteoporosis |
3.4% |
| Pleural Effusion |
3.4% |
| Pneumonia Aspiration |
3.4% |
| Portal Venous Gas |
3.4% |
| Posterior Reversible Encephalopathy Syndrome |
3.4% |
| Pulmonary Alveolar Haemorrhage |
3.4% |
|
| Secondary |
| Product Used For Unknown Indication |
17.9% |
| Hypertension |
11.9% |
| Drug Use For Unknown Indication |
10.9% |
| Helicobacter Infection |
5.8% |
| Ill-defined Disorder |
5.3% |
| Rheumatoid Arthritis |
5.3% |
| Prophylaxis |
4.9% |
| Gastric Ulcer |
4.1% |
| Adult T-cell Lymphoma/leukaemia |
3.8% |
| Insomnia |
3.5% |
| Constipation |
3.4% |
| Myocardial Infarction |
3.2% |
| Angina Pectoris |
3.0% |
| Renal Transplant |
2.7% |
| Hyperlipidaemia |
2.6% |
| Diabetes Mellitus |
2.4% |
| Duodenal Ulcer Perforation |
2.3% |
| Gastritis |
2.3% |
| Gastritis Prophylaxis |
2.3% |
| Pyrexia |
2.3% |
|
| Agranulocytosis |
10.1% |
| Toxic Epidermal Necrolysis |
8.2% |
| Hepatic Function Abnormal |
7.0% |
| Pyrexia |
7.0% |
| White Blood Cell Count Decreased |
7.0% |
| Pneumonia |
5.8% |
| Interstitial Lung Disease |
5.4% |
| Pruritus |
4.7% |
| Vomiting |
4.7% |
| Liver Disorder |
4.3% |
| Sepsis |
4.3% |
| Liver Function Test Abnormal |
3.9% |
| Renal Impairment |
3.9% |
| Thrombocytopenia |
3.9% |
| Colitis Ischaemic |
3.5% |
| Erythema Multiforme |
3.5% |
| Stevens-johnson Syndrome |
3.5% |
| Drug Eruption |
3.1% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
3.1% |
| Lymphocyte Stimulation Test Positive |
3.1% |
|
| Concomitant |
| Rheumatoid Arthritis |
15.2% |
| Prophylaxis |
15.1% |
| Product Used For Unknown Indication |
14.4% |
| Hypertension |
10.6% |
| Drug Use For Unknown Indication |
6.7% |
| Chronic Hepatitis C |
4.5% |
| Constipation |
4.3% |
| Insomnia |
3.7% |
| Gastric Ulcer |
2.9% |
| Diabetes Mellitus |
2.8% |
| Cancer Pain |
2.5% |
| Gastritis |
2.4% |
| Cardiac Failure |
2.4% |
| Osteoporosis |
2.0% |
| Reflux Oesophagitis |
1.8% |
| Metastatic Renal Cell Carcinoma |
1.8% |
| Pain |
1.7% |
| Multiple Myeloma |
1.7% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.6% |
| Hepatitis C |
1.6% |
|
| White Blood Cell Count Decreased |
12.8% |
| Renal Impairment |
8.1% |
| Interstitial Lung Disease |
8.1% |
| Vomiting |
7.7% |
| Pyrexia |
7.1% |
| Pneumonia |
5.4% |
| Platelet Count Decreased |
5.3% |
| Rash |
5.3% |
| Hepatic Function Abnormal |
4.3% |
| Liver Disorder |
4.0% |
| Thrombocytopenia |
4.0% |
| Sepsis |
4.0% |
| White Blood Cell Count Increased |
3.8% |
| Stomatitis |
3.2% |
| Renal Failure |
3.1% |
| Malaise |
3.1% |
| Respiratory Failure |
2.9% |
| Rhabdomyolysis |
2.7% |
| Toxic Skin Eruption |
2.6% |
| Death |
2.6% |
|
| Interacting |
| Fungal Infection |
17.1% |
| Drug Use For Unknown Indication |
15.7% |
| Systemic Lupus Erythematosus |
12.9% |
| Acute Myocardial Infarction |
11.4% |
| Oral Candidiasis |
7.1% |
| Depression |
5.7% |
| Hypertension |
4.3% |
| Angina Pectoris |
2.9% |
| Back Pain |
2.9% |
| Constipation |
2.9% |
| Percutaneous Coronary Intervention |
2.9% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.9% |
| Anxiety |
1.4% |
| Cardiac Pacemaker Insertion |
1.4% |
| Diabetes Mellitus |
1.4% |
| Dizziness |
1.4% |
| Hyperlipidaemia |
1.4% |
| Hyperuricaemia |
1.4% |
| Product Used For Unknown Indication |
1.4% |
| Reflux Oesophagitis |
1.4% |
|
| Drug Interaction |
20.0% |
| In-stent Coronary Artery Restenosis |
20.0% |
| Supraventricular Tachycardia |
20.0% |
| Systemic Mycosis |
20.0% |
| Ventricular Fibrillation |
20.0% |
|
